EXHIBIT N

1	Donald G. Norris (SBN 90000)	
2	Douglas F. Galanter (SBN 93740) Norris & Galanter LLP	
3	523 W. Sixth St., Suite 716 Los Angeles, CA 90014 Tel: 213-232-0855/ Fax: 213-286-9499	
4	dnorris@norgallaw.com dgalanter@norgallaw.com	
5	William F. Cavanaugh (SBN 133461) Scott B. Howard (admitted pro hac vice)	
7	William F. Schmedlin (admitted <i>pro hac vice</i>) Patterson Belknap Webb & Tyler LLP 1133 Avenue of the Americas	
8	New York, NY 10036 Telephone: (212) 336-2000/ Fax: (212) 336-2222 wcavanaugh@pbwt.com	
10	sbhoward@pbwt.com wschmedlin@pbwt.com	
11	Attorneys for Defendants MEDICIS AESTHETICS, INC., MEDICIS PHARMACEUTICAL CORP., VALEANT PHARMACEUTICALS NORTH AMERICA LLC, VALEANT PHARMACEUTICALS INTERNATIONAL,	
12		
13	VALEANT PHARMACEUTICALS INTERNATION LABORATORIES, L.P.	AL, INC., and GALDERMA
14	ENDORMI ORIES, E.I.	
15	UNITED STATES DISTRICT COURT	
16	CENTRAL DISTRICT C	OF CALIFORNIA
17	ALLED CANLUCA INC.	
18	ALLERGAN USA, INC., and ALLERGAN INDUSTRIE, SAS,	Case No. 8:13-cv-01436 AG (JPRx)
20	Plaintiffs,	DEFENDANTS' FIRST SET OF
21	V.	REQUESTS FOR ADMISSION TO PLAINTIFFS ALLERGAN USA, INC.
22	MEDICIS AESTHETICS, INC., MEDICIS PHARMACEUTICAL CORP., VALEANT	AND ALLERGAN INDUSTRIE, SAS (NUMBERS 1-11)
23	PHARMACEUTICALS NORTH AMERICA LLC, VALEANT PHARMACEUTICALS	
24	INTERNATIONAL, VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,	
25	and GALDERMA LABORATORIES, L.P.	
26	Defendants.	
27		
28		DEFENDANTS' FIRST SET OF REQUESTS FOR
	2	ADMISSION TO PLAINTIFFS

Case No. 8:13-cv-01436 A.G.(JPRx)

Pursuant to Rules 26 and 33 of the Federal Rules of Civil Procedure and the Local Rules of the United States District Court for the Central District of California, Defendants Medicis
Aesthetics, Inc., Medicis Pharmaceutical Corp., Valeant Pharmaceuticals North America LLC,
Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc., and Galderma
Laboratories, L.P. ("Defendants") hereby request that Plaintiffs Allergan USA, Inc. and Allergan
Industrie, SAS (collectively, "Allergan" or "Plaintiffs") respond to the Requests for Admission set
forth herein. Defendants further request that Allergan serve a written response, under oath, within
thirty (30) days after service of this request. Answers must be signed and verified by the person
making them and objections signed by the attorney making them. If any objection is made to any
part of any Request for Admission, Allergan shall specify the part of the Request for Admission to
which an objection is made and respond to the remainder.

DEFINITIONS

- 1. "Plaintiffs," "Allergan," "You," or "Your" refer to Allergan USA, Inc. and Allergan Industrie, SAS, and all parents, subsidiaries, divisions, affiliates, officers, and agents thereof.
- 2. "Defendants" means Medicis Aesthetics, Inc., Medicis Pharmaceutical Corp., Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc., and Galderma Laboratories, L.P., collectively.
- 3. "Person" or "Persons" means any individual or firm, association, organization, joint venture, trust, partnership, corporation, or other collective organization or entity.
- 4. "Infringe," "Infringing," and "Infringement" refer to direct infringement, contributory infringement, inducement of infringement, literal infringement, and/or infringement under the doctrine of equivalents.
- 5. "Referring to" and "Relating to" shall mean describing, evidencing, consisting of, pertaining to, reflecting or having any logical or factual connection with the matter discussed.
- 6. "Concerning" shall mean relating to, referring to, describing, evidencing, comprising or constituting.
 - 7. The phrase "475 patent" means and refers to United States Patent No. 8,450,475.

-2-

-3-

1

2

3

4

5

11

28

- 8. The singular form of a word should be interpreted in the plural as well. Any pronoun shall be construed to refer to the masculine, feminine, or neutral gender as in each case is most appropriate. The words "and" and "or" shall be construed conjunctively or disjunctively, whichever makes the request most inclusive.
- 9. The use of a verb in any tense shall be construed as the use of the verb in all other tenses.
- 10. These requests seek all information that is known to You, Your representatives, agents, employees, investigators, consultants and their counsel, or within their possession, custody, and/or control.
- 11. If, after exercising due diligence to secure the information requested, an individual Request or any part thereof cannot be fully answered, please state the reasons for the inability to fully answer, answer the individual Request to the fullest extent possible, and state what information, knowledge, or belief you have concerning the unanswered portion.

REQUESTS FOR ADMISSION

REQUEST FOR ADMISSION NO. 1:

Admit that physicians in the United States added lidocaine to Perlane® immediately before use prior to August 4, 2007.

REQUEST FOR ADMISSION NO. 2:

Admit that physicians in the United States added lidocaine to Restylane® immediately before use prior to August 4, 2007.

REQUEST FOR ADMISSION NO. 3:

Admit that physicians in the United States added lidocaine to the Juvederm® products immediately before use prior to August 4, 2007.

REQUEST FOR ADMISSION NO. 4:

Admit that physicians added lidocaine to Perlane® immediately before use prior to 2005.

REQUEST FOR ADMISSION NO. 5: 1 Admit that physicians added lidocaine to Restylane® immediately before use prior to 2005. 2 **REQUEST FOR ADMISSION NO. 6:** 3 Admit that physicians added lidocaine to Juvederm® products immediately before use prior 4 5 to 2005. 6 **REOUEST FOR ADMISSION NO. 7:** 7 Admit that a physician adding lidocaine to Perlane® immediately before use would not 8 infringe the Patents-in-Suit. 9 **REQUEST FOR ADMISSION NO. 8:** 10 Admit that a physician adding lidocaine to Restylane® immediately before use would not 11 12 infringe the Patents-in-Suit. 13 **REQUEST FOR ADMISSION NO. 9:** 14 Admit that a physician adding lidocaine to Perlane® immediately before use would be an 15 acceptable non-infringing alternative to Perlane-L®. 16 **REQUEST FOR ADMISSION NO. 10:** 17 Admit that a physician adding lidocaine to Restylane® immediately before use would be an 18 acceptable non-infringing alternative to Restylane-L®. 19 20 **REOUEST FOR ADMISSION NO. 11:** 21 Admit that a physician adding lidocaine to Restylane® or Perlane® immediately before use 22 would not be practicing one or more of the claims in the Patents-in-Suit. 23 24 25 Respectfully submitted, Dated: January 13, 2015 26 27 By: /s/ William F. Cavanaugh, Jr. William F. Cavanaugh, Jr. 28 DEFENDANTS' FIRST SET OF REQUESTS FOR -5-ADMISSION TO PLAINTIFFS Case No. 8;13-cv-0143(EXAMERIX)

Case 8:13-cv-01436-AG-JPR Document 147-16 Filed 06/09/15 Page 7 of 8 Page ID #:2793

Attorneys for Defendants MEDICIS AESTHETICS, INC., MEDICIS PHARMACEUTICAL CORP., VALEANT PHARMACEUTICALS NORTH AMERICA LLC, VALEANT PHARMACEUTICALS INTERNATIONAL, VALEANT PHARMACEUTICALS INTERNATIONAL, INC., and GALDERMA LABORATORIES, L.P. -6-DEFENDANTS' FIRST SET OF REQUESTS FOR

1 PROOF OF SERVICE 2 I am employed in the County of New York, my business address is Patterson Belknap Webb 3 & Tyler LLP, 1133 Avenue of the Americas, New York, New York 10036. I am over the age of 18 4 and not a party to the foregoing action. 5 On January 13, 2015, I caused a copy of the following document(s): 6 DEFENDANTS' FIRST SET OF REQUESTS FOR ADMISSION TO ALLERGAN USA, INC. AND ALLERGAN INDUSTRIE, SAS (NOS. 1-11) 7 to be served on the interested parties in this action by ELECTRONIC MAIL, via the email addresses 8 set forth below: 9 brooks@fr.com 10 lgarner@fr.com countryman@fr.com 11 singer@fr.com kane@fr.com 12 coletti@fr.com eflanagan@fr.com 13 Juanita R. Brooks Craig E. Countryman Fish & Richardson P.C. 555 W. 5th Street, 31st Floor 14 Garner Fish & Richardson P.C. 15 12390 El Camino Real Los Angeles, California 90013 San Diego, CA 92130 16 Susan M. Coletti Jonathan E. Singer Elizabeth M. Flanagan 17 Michael J. Kane Fish & Richardson P.C. 222 Delaware Avenue, 17th Floor Fish & Richardson P.C. 18 60 South Sixth Street, Suite 3200 Wilmington, DE 19899 Minneapolis, MN 55402 19 20 I declare under penalty of perjury that the above is true and correct. Executed on January 13, 21 2015, at New York, NY. 22 /s/ William F. Schmedlin 23 William F. Schmedlin 24 25 26 27 28 DEFENDANTS' FIRST SET OF REQUESTS FOR